LFCR (LFCR) Stock Analysis

Verdict: AVOID

Lifecore's high debt load and negative equity overshadow CDMO volume gains, leaving the stock vulnerable after a single-day rally.

Investment score: 34/100

Is LFCR Stock Worth Reviewing? AI Model Thesis

The model flags Lifecore Biomedical as a high-risk speculative profile due to negative equity, $142.6M in debt, and a single-day +55.2% rally that pushed the price above analyst consensus targets.

Should You Buy or Sell LFCR Stock? Model Reasoning

The model identifies a high degree of structural financial risk in Lifecore Biomedical, highlighted by $142.6M in total debt against -$14.2M in stockholders' equity. While the CDMO business generated $129.5M in 2025 revenue with a 29.3% gross margin, ongoing net losses (-$30.8M) and a price target of $6.39 from analysts indicate the current $6.52 price is overextended following a +55.2% speculative single-day move.

LFCR Fair Value & Price Target — AI Valuation

  • Model Assumptions: ["Revenue remains flat to modestly growing at $120M–$130M over 2026–2027 in line with analyst estimates","Gross margin holds near 29%–30%, but high interest expenses keep net margins negative (-29.9%)","No major equity dilution occurs despite negative stockholders equity of -$14.2M and $142.6M total debt"]

LFCR Risk & Opportunity Analysis

Key Investment Risks

  • Negative Stockholders' Equity and Restructuring Risk — Total liabilities ($246.4M) exceeding total assets ($232.2M) leave stockholders' equity at -$14.2M, creating severe restructuring or equity dilution risks.
  • High Debt Burden Relative to Cash Reserves — With $142.6M in total debt against $17.5M in cash, interest expense and debt refinancing could trigger distress if free cash flow turns negative again.
  • Analyst Downgrades and Weak Target Coverage — William Blair downgraded LFCR from Outperform to Market Perform on 2026-09-28, reflecting growing concern over valuation and financial leverage.
  • Valuation Disconnect Post-Rally — The average price target of $6.39 is already surpassed by the current market price of $6.52, leaving minimal fundamental margin of safety.

Growth Opportunities & Upside Drivers

  • CDMO Capacity Expansion and Hyaluronic Acid Demand — Lifecore's specialized multi-channel filling capacity for high-viscosity injectables addresses growing demand in biopharma, supporting 27.26% revenue growth in 2025.
  • Positive Operating Cash Flow Trajectory — Operating cash flow reached $12.57M for the period ending June 2026, generating $6.23M in positive free cash flow after years of cash burns.
  • Current Ratio Cushion — A current ratio of 3.87x and quick ratio of 2.55x provide temporary operational liquidity despite long-term balance sheet distress.
  • Short Squeeze Potential from Low Float — With 33.26M shares outstanding and elevated volume spikes, technical momentum can drive short-term price squeezes above $7.00.

LFCR Action Plan — Entry, Exit and Stop Loss from the Model View

moderate

    aggressive

      conservative

        Frequently Asked Questions About LFCR (LFCR)

        Is LFCR stock a good investment?

        The cached TradeMates AI model rates LFCR as AVOID with an investment score of 34/100. The model flags Lifecore Biomedical as a high-risk speculative profile due to negative equity, $142.6M in debt, and a single-day +55.2% rally that pushed the price above analyst consensus targets. This is algorithmic model output, not personal investment advice.

        Does LFCR pay a dividend?

        The cached stock data on this page does not show a positive dividend yield for LFCR. Dividend status can change, so verify the latest company filings before relying on income assumptions.

        What does LFCR stock do?

        Lifecore Biomedical operates as an integrated contract development and manufacturing organization (CDMO) specializing in highly viscous sterile injectable pharmaceutical drug products and medical devices, as well as bulk pharmaceutical-grade hyaluronic acid (HA).

        What is LFCR stock's price target?

        This cached page does not contain a precise model fair value for LFCR.

        Is LFCR stock a buy?

        The TradeMates model verdict for LFCR is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.

        Is LFCR a good dividend stock?

        LFCR is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

        View the full interactive analysis